Ensho Therapeutics

🗓 Founded 2024👥 11 employees💰 Last funded Aug 2025
Biotechnology Research🌐 enshorx.com
Website LinkedIn
Ensho Therapeutics, Inc. is a privately held, clinical-stage biopharmaceutical company focused on developing breakthrough oral therapies for patients with inflammatory diseases. The company’s initial focus is on a pipeline of oral, selective small molecule inhibitors of lymphocyte homing integrin α4β7 for IBD, a mechanism already validated by a commercially available antibody. Ensho’s assets were acquired from EA Pharma Co., Ltd., a subsidiary of Eisai Co., Ltd., that is focused on gastrointestinal disease. Ensho is preparing to initiate a Phase 2 clinical program in UC with NSHO-101, the lead asset in the company’s pipeline.
1
Total investors
1
Early stage
0
Mid stage
0
Late stage
2024
Founded

Investors

1 investors
All
Early stage
Mid stage
Late stage
Investor geography1 country
United States
1
Frequently asked questions
Who invested in Ensho Therapeutics?
Ensho Therapeutics has 1 investors on record on gritt.io, including 1 early-stage backers.
When did Ensho Therapeutics last raise funding?
The most recent investment in Ensho Therapeutics recorded on gritt.io was in August 2025.
When was Ensho Therapeutics founded?
Ensho Therapeutics was founded in 2024.
What industry is Ensho Therapeutics in?
Ensho Therapeutics operates in Biotechnology Research. Find similar Biotechnology Research investors on gritt.io.